Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Portuguese

Breadcrumb

  1. Home
  2. Microbiota 22 - February 2025
  3. Cultivated Enterococcus faecium B6 from children with obesity promotes non-alcoholic fatty liver disease by the bioactive metabolite tyramine
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
General Medicine

Breadcrumb

  1. Home
  2. Microbiota 22 - February 2025
  3. Cultivated Enterococcus faecium B6 from children with obesity promotes non-alcoholic fatty liver disease by the bioactive metabolite tyramine

Cultivated Enterococcus faecium B6 from children with obesity promotes non-alcoholic fatty liver disease by the bioactive metabolite tyramine

COMMENTED ARTICLE Children’s section

By Pr. Emmanuel Mas
Gastroenterology and Nutrition Department, Children’s Hospital, Toulouse, France

Gastroenterology
Gynecology
Pediatrics
General Medicine
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

Sections

About this article

Created 18 February 2025
Updated 17 March 2025

Comments on the article by Wei et al. (Gut Microbes 2024) [1]

This article explores the relationship between the gut microbiota and non-alcoholic fatty liver disease (NAFLD) in children with obesity, in the context of the global increase in childhood obesity and this disease. The methodology is based on multi-omics analyses and studies of cohorts of children, combined with in vitro and in vivo experiments. The researchers discovered that Enterococcus faecium B6 isolated from these children promoted NAFLD via tyramine production, leading to lipid accumulation, inflammation and liver fibrosis. These findings validate the causal role of this bacterium in NAFLD progression and pave the way for therapeutic approaches based on microorganisms and/or their metabolites.

What do we already know about this subject?

Due to the obesity pandemic, metabolic overload diseases (e.g. NAFLD) have become the main type of liver injury ranging from steatosis, to NASH (non-alcoholic steatohepatitis) and even cirrhosis. NAFLD is now affecting an increasing number of children.

The pathophysiology of NAFLD is complex, but the gut microbiota is thought to play an important role. The effects of the gut microbiota could be mediated by various metabolites, including tyramine.

What are the main insights from this study?

In the first part of the study 156 children with obesity aged between 6 and 18 were enrolled, including 78 with NAFLD and 78 with isolated obesity. The two groups differed in terms of liver and metabolic parameters. Microbial alpha diversity was lower in the NAFLD group. The abundance of Enterococcus, Escherichia, Klebsiella, Dialister and Enterobacter was higher in the NAFLD group, while Faecalibacterium, Eubacterium_eligens_group, Roseburia, Fusicatenibacter, Clostridium, Coprococcus and Parasutterella abundance was lower. Enterococcus was correlated with serum levels of ALT, ASAT, triglycerides and total cholesterol.

Image

E. faecium B6 in the cell culture obtained after isolating bacterial strains from NAFLD children with obesity showed a lipid-accumulating ability. A murine study compared a normal (NCD) or a fat-enriched (HFD) diet, with or without B6, for 12 weeks. Although E. faecium B6 had no effect on body weight, it aggravated overload-related liver damage, both biologically and histologically (figure 1). Transcriptomic analysis revealed that E. faecium B6 modified gene expression in lipid metabolism and inflammation and fibrosis, such as PPAP, chemokine, NF-kB and TGF-β signalling pathways, in linoleic acid metabolism. Regarding lipid metabolism, mRNA and protein expression of PPAR and CD36 were increased, while that of CPT-1a decreased. The authors reported increased expression of inflammatory cytokines (TNF-α, IL-6, IL-1β) and proteins involved in fibrosis (TGF-β and α-SMA) (figure 2).

Image

Using mice serum, a broad, non-targeted analysis via tandem mass spectrometry showed that E. faecium B6 increased or decreased metabolites, when on NCD (30 and 85) or HFD (18 and 45) diets. The most notable change was the increase in tyramine (figure 3). Further analyses have suggested that E. faecium B6 is able to produce tyramine. In addition, treating mice on the NCD or HFD diet with tyramine reproduced the development of NAFLD, without effect on weight, in a similar fashion as that observed with E. faecium B6, and similarly altered the expression of genes encoding PPAR , CD36, CPT-1a, TNF-α, IL-6, IL-1β, TGF-β and α-SMA.

Finally, the authors corroborated these findings in 123 NAFLD children with obesity and in 123 controls. Levels of E. faecium B6 and the gene encoding tyramine (mfnA) were higher in the NAFLD group. These levels were correlated with biological markers of NAFLD (AST, ALAT, triglycerides, total cholesterol and LDL) and inflammatory cytokines (TNF-α, IL-6, IL-1β).

Image

What are the consequences in practice?

This study confirms the importance of the gut microbiota in the development of NAFLD and paves the way for new therapeutic strategies. In addition to Enterococcus faecium B6 and tyramine, PPAR y could play a central role in linking lipid accumulation, inflammation and fibrosis.

Key points
  • E. faecium B6, a bacterium isolated from NAFLD children with obesity, exacerbates the disease by producing a bioactive metabolite, tyramine
  • E. faecium B6 and tyramine reproduce NAFLD in a similar way in mice on normal and high-fat diets

CONCLUSION

This study identified Enterococcus faecium B6 as a strain that promotes the development of NAFLD in children with obesity. This bacterium produces a bioactive metabolite, tyramine, which mediates these effects by activating the PPARy signalling pathway

Sources

1. Wei J, Luo J, Yang F, et al. Cultivated Enterococcus faecium B6 from children with obesity promotes nonalcoholic fatty liver disease by the bioactive metabolite tyramine. Gut Microbes 2024 ; 16 : 2351620.

Tags
Microbiome Flora Obesity
    Focus
    Microbiota 22 - February 2025
    • Overview
      • Helicobacter pylori and gastrointestinal microbiota
    • Commented article
      • The maternal microbiome promotes placental development in mice
      • Cultivated Enterococcus faecium B6 from children with obesity promotes non-alcoholic fatty liver disease by the bioactive metabolite tyramine
    • Congress review
      • Highlights from the DDW congress
      • The first thousand days : a crucial time for Microbiota
    • Press review
      • Gut microbiota #22
      • Vaginal microbiota #22
    • Microbiota observatory 2nd edition
      • International Microbiota Observatory 2nd edition
    Created 18 February 2025
    Updated 17 March 2025

    About this article

    To know more about this topic.

    Content type

    Commented article
    The maternal microbiome promotes placental development in mice
    Highlights from the DDW congress
    Focus

    Microbiota 22 - February 2025

    Overview

    Helicobacter pylori and gastrointestinal microbiota

    Commented article

    The maternal microbiome promotes placental development in mice Cultivated Enterococcus faecium B6 from children with obesity promotes non-alcoholic fatty liver disease by the bioactive metabolite tyramine

    Congress review

    Highlights from the DDW congress The first thousand days : a crucial time for Microbiota

    Press review

    Gut microbiota #22 Vaginal microbiota #22

    Microbiota observatory 2nd edition

    International Microbiota Observatory 2nd edition
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine
    • English
    • Français
    • Español
    • Portuguese

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    14.05.2025

    Towards worldwide redefinition of healthy vaginal microbiota

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    02.05.2025

    A new lens on chlamydia: beyond behavior, into the microbiome

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    © 2025 Biocodex. All rights reserved.

    • Legal notice
    • GTU
    • Data protection policy
    • Sitemap
    • Cookies settings
    • Digital accessibility : partially compliant
    Biocodex logo